Urovant Sciences, a clinical-stage biopharmaceutical company, is focused on developing and commercializing innovative therapies for urologic conditions. Their lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB). The company reported positive data from a phase 3 pivotal study and submitted a New Drug Application to the FDA seeking approval for vibegron. Urovant's second product candidate, URO-902, is a novel gene therapy for OAB patients who have failed oral pharmacologic therapy. The company, owned by Sumitomo Dainippon Pharma Co., Ltd., aims to develop treatments for additional urologic diseases.
Urovant Sciences Ltd.'s ticker is UROV
The company's shares trade on the NASDAQ stock exchange
They are based in Irvine, California
There are 51-200 employees working at Urovant Sciences Ltd.
It is https://urovant.com/
Urovant Sciences Ltd. is in the Healthcare sector
Urovant Sciences Ltd. is in the Biotechnology industry
The following five companies are Urovant Sciences Ltd.'s industry peers: